IN2014DN09717A - - Google Patents

Info

Publication number
IN2014DN09717A
IN2014DN09717A IN9717DEN2014A IN2014DN09717A IN 2014DN09717 A IN2014DN09717 A IN 2014DN09717A IN 9717DEN2014 A IN9717DEN2014 A IN 9717DEN2014A IN 2014DN09717 A IN2014DN09717 A IN 2014DN09717A
Authority
IN
India
Prior art keywords
pdgf
antibodies
inhibiting
binding
pdgfra
Prior art date
Application number
Other languages
English (en)
Inventor
Claudia Fromond
Hoa Thu Ngo
Richard Zwaal
Sofie Notebaert
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Publication of IN2014DN09717A publication Critical patent/IN2014DN09717A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9717DEN2014 2012-04-24 2014-11-18 IN2014DN09717A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
EP12165314 2012-04-24
US201261727231P 2012-11-16 2012-11-16
EP12192943 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (fr) 2012-04-24 2013-04-24 Anticorps anti-pdgf-c

Publications (1)

Publication Number Publication Date
IN2014DN09717A true IN2014DN09717A (fr) 2015-07-31

Family

ID=49482233

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9717DEN2014 IN2014DN09717A (fr) 2012-04-24 2014-11-18

Country Status (13)

Country Link
US (1) US9884910B2 (fr)
EP (1) EP2841454A1 (fr)
JP (1) JP2015515487A (fr)
KR (1) KR20150005631A (fr)
CN (1) CN104321343A (fr)
AU (1) AU2013254690B2 (fr)
BR (1) BR112014025560A2 (fr)
CA (1) CA2871528A1 (fr)
IN (1) IN2014DN09717A (fr)
MX (1) MX2014012843A (fr)
NZ (2) NZ724395A (fr)
RU (1) RU2014140116A (fr)
WO (1) WO2013160359A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841454A1 (fr) 2012-04-24 2015-03-04 ThromboGenics N.V. Anticorps anti-pdgf-c
CN108348605B (zh) * 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
MA45493A (fr) * 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
AU2017290762B2 (en) 2016-07-01 2024-09-12 Paracrine Therapeutics Ab Methods and compositions for PDGF-CC inhibition
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
HRP20230319T1 (hr) * 2017-12-04 2023-05-12 Laboratorios Salvat, S.A. Očni topikalni pripravak koji sadrži dobesilnu kiselinu, namijenjen liječenju bolesti stražnjeg segmenta oka
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
WO2025038442A1 (fr) * 2023-08-11 2025-02-20 Invetx, Inc. Anticorps anti-il-5 et leurs utilisations
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (fr) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Mutant du domaine constant d'immunoglobulines oligomeres presentant une activite cytolytique accrue a mediation de complement
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1064382B1 (fr) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologues aux vegf et bmp1
CN1330664A (zh) 1998-09-30 2002-01-09 路德维格癌症研究所 血小板衍生生长因子c、其编码dna及其应用
WO2000034474A2 (fr) 1998-12-07 2000-06-15 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2001028586A1 (fr) 1999-10-21 2001-04-26 Zymogenetics, Inc. Traitement de la fibrose
WO2001072132A1 (fr) * 2000-03-28 2001-10-04 Ludwig Institute For Cancer Research Animaux transgeniques non humains exprimant un facteur de croissance c derive de plaquettes (pdgf-c) et utilisations
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CA2529798C (fr) * 2003-07-25 2014-09-16 Zymogenetics, Inc. Procedes de traitement de carcinome hepatocellulaire a l'aide d'antagonistes de zvegf3
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
EP2021028A2 (fr) 2006-04-17 2009-02-11 Ludwig Institute For Cancer Research Méthodes et compositions pour moduler la barrière hémato-neurale
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
EP2841454A1 (fr) 2012-04-24 2015-03-04 ThromboGenics N.V. Anticorps anti-pdgf-c

Also Published As

Publication number Publication date
AU2013254690A1 (en) 2014-11-06
BR112014025560A2 (pt) 2017-07-04
MX2014012843A (es) 2017-01-23
KR20150005631A (ko) 2015-01-14
WO2013160359A1 (fr) 2013-10-31
EP2841454A1 (fr) 2015-03-04
JP2015515487A (ja) 2015-05-28
CN104321343A (zh) 2015-01-28
NZ724395A (en) 2018-03-23
US20150232546A1 (en) 2015-08-20
AU2013254690B2 (en) 2017-12-07
CA2871528A1 (fr) 2013-10-31
NZ700274A (en) 2016-10-28
RU2014140116A (ru) 2016-06-10
US9884910B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
IN2014DN09717A (fr)
TN2015000396A1 (en) Antibody drug conjugates
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
IN2014KN00920A (fr)
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
NZ707086A (en) Anti-cd40 antibodies and methods of use
EP3702372A3 (fr) Anticorps humains anti-cd40
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
WO2014163714A3 (fr) Conjugués médicament-anticorps
PH12017500864A1 (en) Anti-notch1 antibodies
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
MX353951B (es) Anticuerpos de anti-teofilina y metodos de uso.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
HK1196831A (en) Lsr antibodies, and uses thereof for treatment of cancer
IL232340A0 (en) lsr antibodies, and their uses for cancer treatment